Skip to main content

14 July 2021

Revving the engine of CAR-T development

Sophie Lutter

White Paper/TheScientist/14 July 2021

Download PDF – 8.7 MB


CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological
malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid
tumours, taking imaginative approaches to overcome the numerous obstacles in the way of turning a hugely
variable starting material into an armed and precisely targeted weapon against cancer. As of Q3 2020, there were
over 500 clinical trials evaluating CAR-T cell therapies worldwide (as registered at, Q3 2020)¹.

Download the resource to continue reading.